DNLI - Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst | Benzinga
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a price target of $38.
Analysts Mayank Mamtani, William Wood, and Brandon Carney said that amid an ongoing innovation wave within central nervous system therapeutics, Denali stands out based on its proprietary blood-brain barrier (BBB) shuttling platform approaches, which enables the safe, efficient, and effective delivery of complex large and small molecules.
The analysts are optimistic about the substantial advancements achieved with the Transport Vehicle (TV) platform, led by ...